Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

MoneyWeek columnist Bill Bonner wrote in the June 28 edition of the U.K. financial publication that the two men running for president of the United States are perfect candidates for a nation in decline. That got me thinking about global stocks.

3 Global Stocks Worth Buying as America Stumbles

GlaxoSmithKline

Novartis

Undervalued pharma stocks can make good investments, whether during times of a booming economy or a faltering one. That is because people will still need medications and healthcare services regardless of the ongoing economic conditions.

The 3 Most Undervalued Pharma Stocks to Buy in July 2024

Novo Nordisk (NVO) is an excellent stock to retain as share prices continue to rise, driven by the stellar performance of GLP-1 drugs. New investors should look for stock price dips to make an entry.

Novo Nordisk (NVO) Soars 38% YTD: How Should You Play the Stock?

Novo's (NVO) efforts to get approval for once-weekly basal insulin icodec in the United States suffer a setback as the FDA issues a CRL.

Novo (NVO) Gets CRL From FDA for Weekly Basal Insulin Icodec

The U.S. Food and Drug Administration has declined to approve Novo Nordisk's weekly insulin in patients with diabetes, the Danish drugmaker said on Wednesday.

US FDA declines to approve Novo Nordisk's weekly insulin

Bagsværd, Denmark, 10 July 2024 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) covering the Biologics License Application for once-weekly basal insulin icodec for the treatment of diabetes mellitus.

Novo Nordisk receives Complete Response Letter in the US for once-weekly basal insulin icodec

Senator Bernie Sanders on Wednesday expressed confidence that Novo Nordisk can be convinced to cut the U.S. prices of its popular Ozempic and Wegovy used for weight loss by publicly shaming the drugmaker over how much it charges compared to prices in other countries.

US Senator Sanders optimistic Novo Nordisk can be pressured to cut Wegovy, Ozempic prices

Eli Lilly

Moderna

Pharmaceutical stocks have not set the world on fire, with a few exceptions. Since the pandemic ended, pharma stocks have largely fallen out of favor with investors amid declining sales and mixed financial results.

3 Pharma Stocks That Could Make Your Grandchildren Rich

Danish drugmaker Novo Nordisk has signed a deal with Indonesia's state-owned pharmaceutical company Bio Farma to produce insulin to combat diabetes in the Southeast Asian country, a Bio Farma senior official said on Wednesday.

Novo Nordisk, Indonesia's Bio Farma sign deal to produce insulin

Shares in Novo Nordisk, maker of the wildly popular obesity drug Wegovy, were down 1.1% on Tuesday after the publication of a data analysis showing rival Eli Lilly's own treatment Mounjaro leads to faster and greater weight loss.

Novo Nordisk shares take a hit after a report revealed Eli Lilly's better weight loss drug

The stock price of a pair of pharmaceutical companies are moving in opposite directions Tuesday following the publication of a new scientific study, with Eli Lilly (LLY) shares rising and American depositary receipts (ADRs) of Danish drugmaker Novo Nordisk (NVO) slipping.

Novo Nordisk Falls as Study Says Eli Lilly Weight-Loss Ingredient More Effective

Novo Nordisk (NYSE:NVO) shares fell and Eli Lilly and Co (NYSE:LLY) rose after a study found the US company's weight-loss drug may be more effective.  Lilly's tirzepatide, branded as Mounjaro, was pitted against semaglutide, which Novo Nordisk (NYSE:NVO) makes under the Wegovy higher-dose brand for weight loss and Ozempic for type-2 diabetes, though the patients in the trial were all taking Ozempic.

Eli Lilly weight-loss drug found more effective than Novo Nordisk's Ozempic

The stock of Danish biotech Novo Nordisk was down 1.6% premarket Tuesday, after a study found that the company's obesity drug Wegovy lags its main rival, Eli Lilly & Co. Inc.'s Mounjaro, in speed and magnitude of weight loss.

Novo Nordisk's stock slumps after study finds Wegovy lags Lilly's Mounjaro in speed and scale of weight loss

An Imperial College spin-out has landed £90 million in Series-A funding backed by heavyweight investors, including an offshoot of the British Business Bank (BBB). Myricx Bio, the recipient of this funding, is at the forefront of developing innovative cancer treatments.

Imperial College spin-out Myricx Bio lands £90m of new investment

Shares in Novo Nordisk , maker of the wildly popular obesity drug Wegovy were down 1.1% on Tuesday after the publication of a data analysis showing rival Eli Lilly's own treatment Mounjaro leads to faster and greater weight loss.

Novo Nordisk shares down after analysis finds Lilly drug leads to better weight loss

Patients lost more significantly more weight on Eli Lilly's Mounjaro than Novo Nordisk's Ozempic, according to a new study.

Patients Lost More Weight On Eli Lilly's Mounjaro Than Novo Nordisk's Ozempic

Agnico Eagle Mines

monday.com

Southern Copper

Vistra Energy

Southern Copper and gold stock Agnico eagle surged above early buy points on hopeful signs for U.S. and China policy.

Copper, Gold Stocks Sparkle, Among 5 Leaders Near Buy Points

Danish drugmaker Novo Nordisk has been reprimanded by UK regulators for failing to disclose fees and expenses paid to individuals and organisations in Britain amounting to about 7.8 million pounds ($9.97 million) between 2020 and 2022.

Novo Nordisk reprimanded in UK for failure to disclose payments to healthcare sector

Novo Nordisk's valuation is high, and the U.S. patent for semaglutide expires in early 2026. However, the drugmaker has a promising pipeline that could drive growth for years to come.

Is It Too Late to Buy Novo Nordisk Stock?

Novo Nordisk (NYSE:NVO) shares have dropped by close to 4% this week, shedding more than £350 billion from its market cap, after a study suggested there may be a link between its blockbuster weight loss drugs Wegovy and Ozempic and vision loss.  Those who have been prescribed the weight-loss injection are at a higher risk of developing an eye condition linked to blindness, the study said.

Novo Nordisk shares drop as study links drugs to vision loss

A new study led by investigators of a Harvard-affiliated teaching hospital found that Novo Nordisk's (NVO) GLP-1 drugs Ozempic and Wegovy could be linked to rare cases of vision loss.

NVO, LLY Slip After Study Links Obesity Drug Use to Vision Loss

Blockbuster weight loss drugs such as Wegovy and Ozempic may be associated with a rare eye condition, according to a new study released Wednesday. A Novo Nordisk spokesperson said there were "key methodological limitations" to the study.

Novo Nordisk shares shrug off concerns over study linking weight loss drugs to rare eye condition

People who use Ozempic or Wegovy for treating obesity or Type 2 diabetes may have an increased risk of developing a rare form of blindness, according to a study published Wednesday in the journal JAMA Network, which Novo Nordisk has criticized for being insufficient.

Using Ozempic Or Wegovy Could Raise Risk For Rare Form Of Blindness, Study Suggests

Novo Nordisk stock skidded Wednesday after a new study suggests its diabetes and weight-loss drug can lead to a blindness-causing disease.

Novo Nordisk, Eli Lilly Tumble After Study Suggests Weight-Loss Drugs Can Lead To Blindness

Amazon

Chipotle

FedEx

HEICO

Occidental Petroleum

Rivian Automotive

The first half of the trading year is in the books, and by all accounts, it was a resounding success. The benchmark S&P 500 index rose 15% from January through the end of June, hitting all-time highs on 31 separate occasions.

News for Novo Nordisk Stock (NVO)